Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q43148419

about

Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review The Role of Autophagy in Hepatocellular Carcinoma Neoplastic disease after liver transplantation: Focus on de novo neoplasms Liver transplantation: immunosuppression and oncology Hepatocellular carcinoma: agents and concepts for preventing recurrence after curative treatment Management of recurrent hepatocellular carcinoma after liver transplant Diagnostic and therapeutic management of hepatocellular carcinoma Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges Comprehensive comparison of three different immunosuppressive regimens for liver transplant patients with hepatocellular carcinoma: steroid-free immunosuppression, induction immunosuppression and standard immunosuppression Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation.Pilot study: rapamycin in advanced hepatocellular carcinoma.Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation.Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.Autophagy and non-alcoholic fatty liver disease.An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm The impact of sirolimus on hepatitis C recurrence after liver transplantation.Rapamycin enhances HBV production by inducing cellular autophagy.Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome.Hepatocellular carcinoma following renal transplantation.Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence.Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database.Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials.Factors predicting survival after post-transplant hepatocellular carcinoma recurrence Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma.Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome.Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients.Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence.Autophagy: A novel therapeutic target for hepatocarcinoma (Review).The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis.Treatment options in hepatocellular carcinoma today.Immunosuppression and hepatocellular carcinoma.Present state of immunosuppressive therapy in liver transplant recipients.

P2860

Q26750463-E0A4B437-E3E3-4776-B6F4-71CB8C0679B2 Q26777419-3148DEB1-C93E-4514-B955-3E95D69A4AA0 Q26798306-28EBC282-DE6E-4938-89E2-DF0305A8FC9C Q26827252-5B0D2842-D4B9-4AAD-B485-E46D365FA85D Q26852299-113062C0-25B7-4D0F-B673-D25A21B70F91 Q26997063-4AF6FC7E-A6BB-44EF-945D-96435DB6E036 Q26999043-81914D68-C087-40A6-BC36-42AE8C55F2F9 Q27005375-2A3A465B-BB8B-4AD8-A921-CB1AD8A4ACBE Q28272678-9CDBAB8B-C951-4462-B6B9-B90C8D9F5007 Q28545113-E25B2E08-F7C5-4D00-9604-0B8BA801368F Q31037974-7246B231-EDF6-4A47-B66D-D32BD4D4890D Q33390766-F29E5C09-42C7-4173-A091-2B77EF89F9E5 Q33905617-8BA62265-1096-48B8-ABA0-EE519B8FE970 Q33932079-AFD7909F-DD1C-4AB5-A621-242383CE5056 Q34200875-A4DC4C1C-9E83-407E-B2AC-19CF191534B4 Q34247340-5ACFE797-3AC1-41FB-B99F-018F3C667978 Q34417009-9E8FB60F-D87B-468B-A77F-49C295840ECC Q34522556-FC8C9D73-4E48-491C-9B5A-9DC699E0B1D5 Q34546155-D852EE4F-0100-4BBC-8B51-91C17A0BBFD9 Q35626757-9C5E8805-D33B-4A83-8C44-3723BA37794A Q35715435-BA4B84CB-5C32-4CD6-BF65-10A356419C93 Q35779474-B6674B3D-B926-45AA-A945-3DBBED43DE3F Q35818336-DD865A5A-4007-4CFB-8576-1403BFFBAE6E Q36015895-F48039B0-6CDD-423E-B47E-14244A417D91 Q36102839-5C2EE1F7-2ABA-4406-AE21-474E345A0460 Q36381360-9294D053-39F4-4403-8E11-53A3CF76AEDA Q36414078-69BD92CB-BA49-4B1D-B6E8-BD87CB5C5A96 Q36662813-DF8D0C7F-C86F-4861-938A-387B054C4A1B Q36840196-8D41036C-B84D-43E8-B159-011C915E9C58 Q36962089-36A05E27-9E7A-4A48-B3A5-35788EAF59D7 Q37088225-CE64FD2E-230F-4093-8463-DE7F093440E7 Q37355472-371449D9-88C0-4DC8-A821-EAFFB1C70F2B Q37454420-B4AC37B7-D48E-4C26-B193-B2397057BBE8 Q37605371-13B43D96-61ED-48FC-B303-0D047B476263 Q37639714-4A55EA7D-49F1-48B6-84DD-AE68EFC81F95 Q37720015-A4362870-C1EB-400D-96C1-D426792196B2 Q37759310-FC38C348-1A7B-48ED-8CB4-83F7B189D5D3 Q37863929-048EAD61-CED7-4030-99FB-1BA1DA9256BA Q37867072-8E69045D-867F-457B-B2B8-893784DA36CC Q37919421-1D5D5809-7DE2-4E44-9212-1965A4CE4110

P2860

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q43148419

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Sirolimus-based immunosuppress ...... for hepatocellular carcinoma.

@en

Sirolimus-based immunosuppress ...... for hepatocellular carcinoma.

@nl

type

label

Sirolimus-based immunosuppress ...... for hepatocellular carcinoma.

@en

Sirolimus-based immunosuppress ...... for hepatocellular carcinoma.

@nl

prefLabel

Sirolimus-based immunosuppress ...... for hepatocellular carcinoma.

@en

Sirolimus-based immunosuppress ...... for hepatocellular carcinoma.

@nl

P1433

Q43148419-79EF9791-CCA5-4892-A030-F2295B100F2B

P1476

Q43148419-92D3B6B9-D5BF-47C2-A33D-162D8DB6869B

P2093

Q43148419-48195FA2-421E-4DC7-B15B-33C09901E61D

Q43148419-625D2226-69FE-46F0-A298-68C9125A33F1

Q43148419-C9910E45-6E3C-40B2-8DD9-CC4D57F1F4AA

Q43148419-E3B161AA-9B1D-4AFA-97D5-8C1C329B745E

P2860

Q43148419-01E599CA-65DA-482D-BBBE-FE0193F31DB7

Q43148419-0840BB91-9ECF-4C36-A15E-B7497643910F

Q43148419-0A8B1F37-21E7-49C0-8826-AF724EC570E4

Q43148419-18D919BC-282C-4BC1-9647-8F7437BB50FF

Q43148419-22B4DEF7-CCF8-4CAA-BA55-A98CB9B4FB04

Q43148419-513FA61F-7D22-4BAD-B227-F630912EAE0A

Q43148419-68619E11-F66A-47D0-BEDB-7FBC5B24BB3B

Q43148419-6C262CAE-67A9-4C05-BC9F-822596147EC4

Q43148419-732A9BEA-1FE1-4753-99CC-5A0E20F93A11

Q43148419-74155732-BC0E-458E-8423-0EFDAE55CDCC

P304

Q43148419-FAA1FF66-5C37-4276-80E8-82BA81F99EBB

P31

Q43148419-816D28EE-D558-4ECB-BF18-9E0CEB49EFBB

P356

Q43148419-B4A1BAC6-ED63-4B01-9C78-242CEEB6EC9E

P407

Q43148419-AA711272-EDED-43A2-9771-A9AAAB950FAD

P433

Q43148419-837697DB-393F-4CBB-BBDC-79832B76A85E

P478

Q43148419-80EBBC36-2DDF-44AE-AB71-EC4B215D4F3D

P50

Q43148419-0F582F06-8CC8-462C-9B26-37D28E6DBA41

P577

Q43148419-9750BC8A-9D85-437A-815A-FF24AA1188B4

P5875

Q43148419-9403754B-313F-4F1F-83D9-598E6A7775E6

P698

Q43148419-FB35B6B1-DDAC-4B53-A844-4B988B4BD2D8

P921

Q43148419-A2D21E3F-8A7A-4820-87EB-AEA28C48828E

Q43148419-E6BF5D52-39FF-43EA-9F9F-0F16F5D99FBA

P356

P1433

P1476

Sirolimus-based immunosuppress ...... n for hepatocellular carcinoma

@en

P2093

A M James Shapiro

http://www.w3.org/2001/XMLSchema#string

Christian Toso

http://www.w3.org/2001/XMLSchema#string

David L Bigam

http://www.w3.org/2001/XMLSchema#string

Norman M Kneteman

http://www.w3.org/2001/XMLSchema#string

P2860

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.

A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications.

Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.

Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria.

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.

Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth.

Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma.

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications.

P304

1237-1243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.23437

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41579761

http://www.w3.org/2001/XMLSchema#string

P698

20187107

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation

immunosuppression